Clinical Trial Update: Rosiglitazone and Insulin Resistance in Renally Impaired Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating rosiglitazone for insulin resistance in patients with chronic kidney disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Insulin Resistance

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Chronic Kidney Disease, Insulin Resistance | Phase 3 | Status: TERMINATED